You can buy or sell BioTime and other stocks, options, ETFs, and crypto commission-free!
BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Read More Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 10
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels (approximately $2.5 million USD) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, the Company’s retinal pigment epithelium transplant therapy currently in Phase I/IIa...
Seeking AlphaMay 10
BioTime, Inc. CEO Brian Culley on Q1 2019 Results - Earnings Call Transcript
BioTime, Inc. (NYSEMKT:BTX) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Ioana Hone - Director of Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Ed Wirth - Chief Medical Officer Gary Hogge - Senior Vice President of Clinical & Medical Affairs, Conference Call Participants Kevin DeGeeter - Oppenheimer Jason McCarthy - Maxim Reni Benjamin - Raymond James Operator Welcome to the BioTime, Inc., First Quarter 2019 Ear...
-$0.06 per share
$0.30 per share